TY - JOUR
T1 - Synthesis, spectroscopic characterizations, single crystal X-ray analysis, DFT calculations, in vitro biological evaluation and in silico evaluation studies of thiosemicarbazones based 1,3,4-thiadiazoles
AU - Palakkeezhillam, Vishnunarayanan Namboothiri Vadakkedathu
AU - Haribabu, Jebiti
AU - Manakkadan, Vipin
AU - Rasin, Puthiyavalappil
AU - Varughese, Roslin Elsa
AU - Gayathri, Dasararaju
AU - Bhuvanesh, Nattamai
AU - Echeverria, Cesar
AU - Sreekanth, Anandaram
N1 - Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2023/2/5
Y1 - 2023/2/5
N2 - We created new thiosemicarbazones and their cyclized heterocyclic compounds, examined them, and evaluated their biological activity in silico and in vitro. Two pyrene-based thiosemicarbazone compounds, (E)-N'-(pyren-1-ylmethylene) pyrrolidine-1-carbothiohydrazide (PP1) and (E)-N'-(pyren-1-ylmethylene) morpholine-4-carbothiohydrazide (PM1) were prepared from pyrrolidine-1-carbothiohydrazide and morpholine-4-carbothiohydrazide with pyrene-1-carboxaldehyde. The 2-(pyren-1-yl)-5-(pyrrolidin-1-yl)-1,3,4-thiadiazole (PP2) and 4-(5-(pyren-4-yl)-1,3,4-thiadiazol-2-yl)morpholine (PM2) were obtained unexpectedly from the cyclization of PP1 and PM1 in the presence of Mn(OCOCH3)2⋅4H2O. FT-IR, UV-Visible, NMR, and HR-MS were used to accurately portray the structure of the compounds. The molecular composition of PP1, PP2 and PM2 were ascertained by the single-crystal X-ray diffraction (XRD) method. The compounds are ordered and dispersed in three dimensions according to the density functional theory (DFT) findings, which are in good agreement with the XRD-derived crystal structures. The molecular docking analysis revealed the various possible interactions of drugs with the non-small cell lung cancer protein (EGFR with a non-covalent inhibitor). The binding energies for the compounds were found to be in the following order PP2 > PP1 > PM1 > PM2, and molecular dynamic simulation was used to further examine the binding mechanism of the most active compound (PP2). These compounds bound strongly with calf thymus (CT)-DNA, which was well described by absorption and emission studies. This demonstrated that PP2 had a better ability to bind (Kb value of 1.95 × 106 and Kq value of 2.43 × 104). Similarly, the synergy of bovine serum albumin (BSA) with compounds also was examined and showed PP2's significant binding potential (Kb value of 2.94 × 104 and Kq value of 6.87 × 104). Additionally, using an MTT assay against a few human cancer cells, the substances' in vitro cell viability was evaluated, including HepG-2 (hepatocellular carcinoma) and T24 (bladder), as well as Vero (normal kidney epithelial cells isolated from an African green monkey). With IC50 values of 13.16 μM (Cisplatin-IC50 = 49.9 μM) and 37.67 μM (Cisplatin-IC50 = >50 μM), respectively, the findings demonstrated that PP2 displayed efficient cytotoxicity towards HepG-2 and T24 cells.
AB - We created new thiosemicarbazones and their cyclized heterocyclic compounds, examined them, and evaluated their biological activity in silico and in vitro. Two pyrene-based thiosemicarbazone compounds, (E)-N'-(pyren-1-ylmethylene) pyrrolidine-1-carbothiohydrazide (PP1) and (E)-N'-(pyren-1-ylmethylene) morpholine-4-carbothiohydrazide (PM1) were prepared from pyrrolidine-1-carbothiohydrazide and morpholine-4-carbothiohydrazide with pyrene-1-carboxaldehyde. The 2-(pyren-1-yl)-5-(pyrrolidin-1-yl)-1,3,4-thiadiazole (PP2) and 4-(5-(pyren-4-yl)-1,3,4-thiadiazol-2-yl)morpholine (PM2) were obtained unexpectedly from the cyclization of PP1 and PM1 in the presence of Mn(OCOCH3)2⋅4H2O. FT-IR, UV-Visible, NMR, and HR-MS were used to accurately portray the structure of the compounds. The molecular composition of PP1, PP2 and PM2 were ascertained by the single-crystal X-ray diffraction (XRD) method. The compounds are ordered and dispersed in three dimensions according to the density functional theory (DFT) findings, which are in good agreement with the XRD-derived crystal structures. The molecular docking analysis revealed the various possible interactions of drugs with the non-small cell lung cancer protein (EGFR with a non-covalent inhibitor). The binding energies for the compounds were found to be in the following order PP2 > PP1 > PM1 > PM2, and molecular dynamic simulation was used to further examine the binding mechanism of the most active compound (PP2). These compounds bound strongly with calf thymus (CT)-DNA, which was well described by absorption and emission studies. This demonstrated that PP2 had a better ability to bind (Kb value of 1.95 × 106 and Kq value of 2.43 × 104). Similarly, the synergy of bovine serum albumin (BSA) with compounds also was examined and showed PP2's significant binding potential (Kb value of 2.94 × 104 and Kq value of 6.87 × 104). Additionally, using an MTT assay against a few human cancer cells, the substances' in vitro cell viability was evaluated, including HepG-2 (hepatocellular carcinoma) and T24 (bladder), as well as Vero (normal kidney epithelial cells isolated from an African green monkey). With IC50 values of 13.16 μM (Cisplatin-IC50 = 49.9 μM) and 37.67 μM (Cisplatin-IC50 = >50 μM), respectively, the findings demonstrated that PP2 displayed efficient cytotoxicity towards HepG-2 and T24 cells.
KW - DFT calculations
KW - In vitro cytotoxicity
KW - Molecular docking
KW - Molecular dynamic simulation
KW - Thiadiazole
KW - X-ray crystallography
UR - http://www.scopus.com/inward/record.url?scp=85139867045&partnerID=8YFLogxK
U2 - 10.1016/j.molstruc.2022.134309
DO - 10.1016/j.molstruc.2022.134309
M3 - Article
AN - SCOPUS:85139867045
SN - 0022-2860
VL - 1273
JO - Journal of Molecular Structure
JF - Journal of Molecular Structure
M1 - 134309
ER -